Why there is no single star rating
Peptide claims often mix different questions into one confidence signal. This methodology keeps efficacy, safety, regulatory status, and product quality separate so it is clear where certainty is strong and where it is missing.
Sample scorecard
Evidence scorecard
A sample uncertainty-heavy profile: weak human efficacy, sparse safety data, and high regulatory/product-quality risk.
- Efficacy
- 1/5limited
- Safety
- 1/5limited
- Regulatory risk
- 4/5high
- Product quality risk
- 4/5high
Rubric
| Dimension | How to read it |
|---|---|
| Efficacy | 0 means unavailable; 5 means strong replicated human evidence for the claimed use. |
| Safety | 0 means unavailable; 5 means broad labeled or well-characterized human safety data. |
| Regulatory risk | 0 means approved labeled use; 5 means clear enforcement, category concern, or illegality risk. |
| Product quality risk | 0 means approved GMP product; 5 means research-use, counterfeit-prone, or unverifiable supply. |
Dose and protocol language
When a source names a regimen or label schedule, Peptides Media identifies the evidence behind it and keeps that information separate from advice.
Sources
- 1.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.